Alzheimer's Disease: NPI-001 Study

We are testing a new oral medication, NPI-001, for people aged 50 to 85 with Mild Cognitive Impairment or mild dementia due to Alzheimer's. The study aims to assess its safety and effects on brain health and cognitive function.

1-2 years 11-15 visits Efficacy phase (II)Partially Remote Standard Medicines OralInternal MedicineNeurology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Acetylcysteine

Acetylcysteine helps thin and loosen mucus to clear airways in respiratory conditions and treats acetaminophen (paracetamol) overdose.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Sanos A/S

Medicine

Nørresundby, Denmark

Sanos A/S

Medicine

Rødovre, Denmark

Sanos A/S

Medicine

Vejle, Denmark

Sponsor: Arctic Therapeutics ehf.

Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.